D.E. Shaw & Co
NBRV

D.E. Shaw & Co’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

D.E. Shaw & Co’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-79
Closed -$40K – 4261
2019
Q3 		$40K Buy
+79
New +$44.6K ﹤0.01% 3737
2019
Q2 		– Sell
-485
Closed -$296K – 3977
2019
Q1 		$296K Buy
+485
New +$265K ﹤0.01% 3223
2018
Q4 		– Sell
-103
Closed -$70K – 4110
2018
Q3 		$70K Buy
+103
New +$73K ﹤0.01% 3640
2017
Q4 		– Sell
-345
Closed -$706K – 3818
2017
Q3 		$706K Buy
+345
New +$809K ﹤0.01% 2711

Other funds holding NBRV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co's NBRV Position: Q4 2019 in Review

D.E. Shaw & Co sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q4 2019, closing a stake of 79 shares — an estimated $40K sold.

D.E. Shaw & Co first reported a position in NBRV in Q3 2017 and held it in 4 quarters. The position peaked at $706K in Q3 2017. 50 funds tracked by Wall St. Rank hold NBRV as of Q4 2019.

  • D.E. Shaw & Co reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q4 2019 after selling out during the quarter.
  • D.E. Shaw & Co sold 79 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q4 2019, an estimated $40K.
  • D.E. Shaw & Co first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q3 2017 and held it in 4 quarters.
  • D.E. Shaw & Co's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $706K in Q3 2017.
  • 50 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q4 2019.

Based on D.E. Shaw & Co's 13F filing for Q4 2019, filed 14 Feb 2020.